CSL Ltd. — Investor Presentation 2021

Oct 18, 2021

==> picture [205 x 32] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

For immediate release

19 October 2021

CSL’s Annual R&D Day - 2021

CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL will hold its annual Research and Development briefing today; the presentation is attached for the information of investors.

Amongst other achievements, CSL is pleased to highlight the following:

• CSL’s Seqirus business advances first-of-its-kind adjuvanted, cell-based seasonal influenza vaccine (aQIVc) and increases work on its selfamplifying mRNA (sa-mRNA) development program. Earlier this month, the Biomedical Advanced Research and Development Authority (BARDA) awarded Seqirus a multi-year contract to provide clinical development services to evaluate the safety, immunogenicity, and dose-sparing capability of two H2Nx influenza vaccine candidates: one using a combination of Seqirus’ FDA-licensed cell-based and adjuvanted technologies, and the other using its next generation sa-mRNA platform.

• New collaboration with the Walter and Eliza Hall Institute for Medical Research (WEHI), one of the most prominent medical research and medicine development organisations in Australia, to create a Centre for Biologic Therapies.

• Phase III study of 4-Factor Prothrombin Complex Concentrate to improve survival in traumatic injury and acute major bleeding will be initiated and the VANGUARD Phase III clinical trial for Garadacimab, a treatment in hereditary angioedema (HAE), enrolled its last patient – two months ahead of schedule. Additionally, recruitment from the AEGIS-II Phase III study of CSL112 (ApoA-1) for treatment of acute coronary syndrome is progressing despite COVID-19 impact on clinical trial sites and patients. More than 14,000 people have been enrolled in this study to date.

• Preparations are underway for EtranaDez, a gene therapy for haemophilia B, to submit a Biologics Licensce Application for the US and Marketing Authorisation Application for the EU.

• Overall, R&D investment was more than $1 billion in the past fiscal year -- across six therapeutic areas (immunology, haematology, respiratory, cardiovascular and metabolic, transplant, influenza), four scientific platforms (plasma fractionation, recombinant technology, cell and gene therapy, vaccines) and two businesses (CSL Behring and Seqirus).

==> picture [99 x 7] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Page 2

19 October 2021

“We continue to evolve as a leading plasma-based biotechnology company with purposeful diversity in therapeutic areas, scientific platforms and strategic alliances,” said Dr. Bill Mezzanotte, Executive Vice President, Head of R&D, Chief Medical Officer for CSL. “We are continuing to invest in our core plasma business while also enhancing our other scientific platforms to better deliver on our promise to discover, develop and provide innovations that save and improve lives around the world.”

Shareholders can access the briefing through CSL’s website at CSL.com.au.

Approved for Release

Fiona Mead Company Secretary

For further information, please contact:

Investors:

Mark Dehring Head of Investor Relations Communications Phone: +61 3 9389 3407 Email: Mark.Dehring@csl.com.au

Media: Jimmy Baker Global Finance

Phone: +61 450 909 211 Email: Jimmy.Baker@csl.com.au

==> picture [99 x 7] intentionally omitted <==

==> picture [101 x 89] intentionally omitted <==

R&D Investor Briefing 2021 October 19, 2021

Important Notice and Disclaimer

Legal Notice

This presentation contains summary information about CSL Limited (ACN 004 089 936) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research and risk management practices. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements. . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

Trademarks

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

2

==> picture [55 x 99] intentionally omitted <==

Introduction William Mezzanotte MD Executive Vice President, Head of R&D and Chief Medical Officer CSL Behring

==> picture [109 x 9] intentionally omitted <==

==> picture [35 x 19] intentionally omitted <==

3

	Agenda
	01 Welcome Mark Dehring 02 Introduction – FY21 Retrospective & Highlights Bill Mezzanotte 03 Research Andrew Nash 04 Development Deirdre BeVard
	Commercial Bill Campbell Seqirus Russell Basser & Ethan Settembre Looking toward FY22 & Summary Bill Mezzanotte Q&A Panel 05 06 07 08

4

Commitment to Research and Development

==> picture [512 x 228] intentionally omitted <==

----- Start of picture text -----

$1,001
$922
$832
$702
$667
16-17 17-18 18-19 19-20 20-21
----- End of picture text -----

New Product Development activities focus on innovative new therapies for life-threatening diseases

Market Development

strategies seek to bring therapies to new markets and new indications

Life Cycle Management ensures continuous improvement of existing products

R&D investment ~10-11% global revenue*

• Investment reported in US$ millions; Includes R&D for CSL Behring and Seqirus

5

Key Past Launches from R&D Portfolio

Influenza Vaccines Immunology Haematology	FY17 FY18 FY19 FY20 FY21	FY17 FY18 FY19 FY20 FY21	FY17 FY18 FY19 FY20 FY21	FY17 FY18 FY19 FY20 FY21	FY17 FY18 FY19 FY20 FY21
	PRIVIGEN® CID HAEGARDA®(US)	P (US) HIZENTR CIDP	HIZENT CIDP (J A® PRIVIGE CIDP (JP	RA® P) N® ) PRIVIGE PID/SID	N® (JP)
	AFSTYLA®				IDELVION® 21-Day (EU) IDELVION® 21-Day (JP)
		FLUCELVAX® QIV (US) FLUAD®(UK)	FLUCEL QIV 9yrs AFLURIA® QIV 6m (A	VAX® + (EU, CA) o+ U) FLUA FLU FL 9y	D® QIV (US) AD® QIV (EU) UCELVAX® QUAD rs+ (AU)

• Expanded label for dosing every 21 days for patients ≥12 years in age, depending on individual patient and efficacy (and jurisdiction)

6

==> picture [912 x 441] intentionally omitted <==

----- Start of picture text -----

3500 IU PFS 2yr+ approval
Notable Regional Regulatory Action CSL889 (Hemopexin)
(treatment SCD)
2yr+ age extension
1 July 2020 – 30 June 2021 approval
3500 IU
Pediatric Indication 21d dosing For MMN
CSL889 (Hemopexin)
(treatment SCD)
CIDP optimized dosing
21d dosing
2yr+ age extension approval Pediatric Indication
CIDP Indication
AlbuRx [®]
Pediatric Indication
3500 IU
AlbuRx [®] Beriate [®]
Hepatitis B-Ig
Behring 9yrs+
4yr+ full approval PFS
6mo-4yr indication
New Initial Marketing New Line Extensions/
Orphan Drug Designation
Authorization Approvals Indications Approvals
----- End of picture text -----

• Every 21 days in patients ≥12 years of age, depending on individual patient and efficacy (and jurisdiction) Abbreviations: SCD - Sickle Cell Disease; PFS - Pre-filled Syringe; MMN - Multifocal Motor Neuropathy; CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

7

Focus Through Our Therapeutic Areas and Platforms

==> picture [960 x 230] intentionally omitted <==

----- Start of picture text -----

Therapeutic Areas
Immunology Haematology Respiratory Cardiovascular Transplant Influenza Vaccines
and Metabolic (Seasonal, Pandemic)
Adjuvanted
Plasma Recombinant Cell and
Platform Cell-based Egg-based
Fractionation Technology Gene Therapy
sa-mRNA
----- End of picture text -----

8

R&D Highlights – FY21

==> picture [43 x 43] intentionally omitted <==

Immunology

• HIZENTRA[®] 5 ~~-~~ , 10 ~~-~~ & 20 ~~-~~ mL pre ~~-~~ filled syringes launched in US

• PRIVIGEN[®] for CIDP launched in Japan

• HAEGARDA[®] approval for paediatric patients (US, AU & CA)

• HAEGARDA[®] ODD approved in Japan

• First patients enrolled in Garadacimab Phase III studies

==> picture [43 x 43] intentionally omitted <==

Cardiovascular & Metabolic

• CSL112 (ApoA ~~-~~ 1) Phase III study (AEGIS ~~-~~ II) >13,000 patients enrolled, successful completion of 1[st] & 2[nd] futility analyses

• First patient enrolled in CSL346 Anti ~~-~~ VEG ~~-~~ B DKD Phase II study

==> picture [43 x 43] intentionally omitted <==

----- Start of picture text -----

Haematology
----- End of picture text -----

Haematology

• uniQure announced positive data from Phase III trial of EtranaDez

• Anti ~~-~~ trust clearance received; licence agreement with uniQure completed for EtranaDez

• CSL889 Hemopexin ODD approved in EU & US

• CSL889 Hemopexin fast track designation for SCD approved by US FDA; first patient enrolled in Phase I study

• IDELVION[®] 21 day extended dosing option approved in Japan

• Recombinant FIX approved in Mexico as IDELVIAN

• AFSTLYA[®] approved in Great Britain, Russia & Mexico

==> picture [43 x 43] intentionally omitted <==

Respiratory

• First patient enrolled in CSL787 Nebulised Ig Phase I study

==> picture [43 x 44] intentionally omitted <==

Transplant

• Last patient dosed in Part 1 of CSL964 for prevention of GvHD study

==> picture [43 x 43] intentionally omitted <==

Influenza Vaccines

• Commencement of aQIVc Phase II study

• Pre-clinical assessment of self-amplifying mRNA vaccine for seasonal & pandemic influenza

9

R&D Portfolio – October 2020

Registration/ Post-Registration

==> picture [840 x 244] intentionally omitted <==

----- Start of picture text -----

Research Pre-Clinical PhaseI PhaseII Phase III Post-Registration
Gene Therapy CSL888 CSL324 HIZENTRA [®] HIZENTRA [[®]] PRIVIGEN [[®]]
Treatments Haptoglobin(SAH) Anti-G-CSFR mAb(HS) (SSc) (DM) (PID) JP
PID
CSL510 CSL730 CSL630 HAEGARDA [[®]] IDELVION [[®]]
DiscoveryProjects Modified Fibrinogen rFcMultimer pdFVIII Ruide Japan rFIX-FP (HaemB)
CSL040 CSL889 CSL346 Garadacimab AFSTYLA [[®]]
DiscoveryProjects Novel Complement Hemopexin(SCD) Anti-VEGF-B mAb Anti-FXIIa mAb(HAE) rFVIII (HaemA)
Inhibitor (DKD)
CSL200 EtranaDez ZEMAIRA [[®]] /RESPREEZA [[®]]
DiscoveryProjects sa-mRNA Influenza CAL-H(SCD) Garadacimab Etranacogene Alpha1-Proteinase
Vaccine Anti-FXIIa mAb(ILD/IPF) dezaparvovec Inhibitor
CSL787
DiscoveryProjects LASN01 NebulisedIg Garadacimab KCENTRA [[®]] AFLURIA [[®]] QUAD
Anti-IL-11R Anti-FXIIa mAb(ARDS) 4F-PCC (Trauma) Egg-based Influenza
CSL311 Vaccine
DiscoveryProjects P. Gingivalis Anti-Beta Common mAb Adjuvanted Cell Culture CSL112
(Periodontal Disease) Influenza Vaccine ApoA-1(ACS) FLUCELVAX [[®]]
UQ/CSL V451 (aQIVc) Quadrivalent
(aCoV2) Clazakizumab Cell-based Influenza Vaccine
Mavrilimumab Anti-IL-6 mAb(AMR)
CSL334/ASLAN004 Anti-GM-CSFR mAb FLUAD [[®]] Quadrivalent
Anti-IL-13R mAb(AD) CSL964 Adjuvanted Influenza
----- End of picture text -----*

HIZENTRA[[®]] PRIVIGEN[[®]] (DM) (PID) JP HAEGARDA[[®]] IDELVION[[®]] Japan rFIX-FP (HaemB) Garadacimab AFSTYLA[[®]] Anti-FXIIa mAb(HAE) rFVIII (HaemA) EtranaDez* ZEMAIRA[[®]] /RESPREEZA[[®]] Etranacogene Alpha1-Proteinase dezaparvovec Inhibitor KCENTRA[[®]] AFLURIA[[®]] QUAD 4F-PCC (Trauma) Egg-based Influenza Vaccine CSL112 ApoA-1(ACS) FLUCELVAX[[®]] Quadrivalent Clazakizumab Cell-based Influenza Vaccine Anti-IL-6 mAb(AMR) FLUAD[[®]] Quadrivalent CSL964 Adjuvanted Influenza Alpha-1Antitrypsin Vaccine (Treatment of GvHD) AUDENZ™ CSL964 Adjuvanted Monovalent Alpha-1Antitrypsin Influenza A (H5N1) Vaccine (Prevention of GvHD) COVID-19 Hyperimmune Therapy

• Transaction with uniQure is subject to customary regulatory clearances before closing

Immunology Haematology Respiratory Cardiovascular & Metabolic Transplant Influenza Vaccines COVID Outlicensed Programs Partnered Projects

10

R&D Product Progression in FY21

==> picture [670 x 317] intentionally omitted <==

----- Start of picture text -----

Registration/
Phase II Phase III Post-Registration
aQIVc Garadacimab HAEGARDA [®]
MF59 [®] plus Anti-FXIIa mAb(HAE) HAE
FLUCELVAX [®] antigen
CSL964 HIZENTRA [®]
Alpha-1Antitrypsin (SCIg) 20% Liquid
(Prevention of GvHD)
PRIVIGEN [®]
(IVIg) 10% Liquid
AUDENZ™
Adjuvanted Monovalent
Influenza A (H5N1) Vaccine
FOCLIVIA [®] /FOCETRIA
Adjuvanted Egg-based
Influenza A (H5N1) Vaccine
PANVAX [®]
Egg-based Influenza
Vaccine
----- End of picture text -----

Immunology Transplant Influenza Vaccines

11

Kcentra[®] in Trauma

Trauma is the leading cause of morbidity and mortality in the US*

Haematology

Haemorrhage is the most common, preventable cause of early death following Trauma

~880k patients suffer traumatic injury annually in US

==> picture [111 x 110] intentionally omitted <==

~85% of haemorrhagic deaths occur within 6 hours

35-40%

of Trauma patients experience life threatening Acute Major Bleeding (AMB)

==> picture [38 x 35] intentionally omitted <==

==> picture [38 x 39] intentionally omitted <==

Through early administration in the Emergency Department, Kcentra[®] is intended to restore effective hemostasis, stop bleeding quickly, and improve survival of Trauma patients with AMB Data from preclinical and clinical studies[1-3] support use of Kcentra[®] in trauma resuscitation

Trauma and 4-F PCC Phase III Study

• Kcentra[®] + Standard of Care vs. Standard of Care

• Primary endpoint: 6-hr all-cause mortality

• Up to 8,000 patients

==> picture [206 x 139] intentionally omitted <==

• Among children, adolescents and young adults 1-44 years old Abbreviations: 4-F PCC- Four-Factor Prothrombin Complex Concentrate

1 Ghosh, S. et al., (2021) https://doi.org/10.1371/journal.pone.0258192

2 Zeeshan, M. et al., (2019) J Trauma Acute Care Surg 87(2):274-281

3 Joseph, B. et al., (2014) World J Surg 38(8):1875-81

12

Hizentra[® ] Secondary Immune Deficiency (SID)

• Infections Remain Leading Cause of Death in Chronic Lymphocytic Leukemia (CLL) – Effective Infection Prevention is an Unmet Need

==> picture [114 x 114] intentionally omitted <==

Phase III Efficacy, Safety and Pharmacokinetic Study of Hizentra[®] for Prevention of Infection in Adults with CLL and Hypogammaglobulinemia

==> picture [640 x 163] intentionally omitted <==

----- Start of picture text -----

Safety follow-up (4 weeks)
Hizentra [®]
Placebo
Week 1 Week 56
Screening End of study
Randomisation End of treatment
----- End of picture text -----

• Study Objective : Demonstrate benefit of treatment with subcutaneous immunoglobulin in prevention of infections in patients with CLL and hypogammaglobulinemia

13

==> picture [55 x 99] intentionally omitted <==

Research Andrew Nash PhD

==> picture [115 x 115] intentionally omitted <==

Senior Vice President, Research and Chief Scientific Officer CSL Behring

==> picture [109 x 9] intentionally omitted <==

==> picture [35 x 19] intentionally omitted <==

14

CSL Behring Research

CSLB Global Research

==> picture [117 x 77] intentionally omitted <==

==> picture [100 x 73] intentionally omitted <==

==> picture [80 x 46] intentionally omitted <==

==> picture [36 x 40] intentionally omitted <==

==> picture [107 x 55] intentionally omitted <==

==> picture [117 x 51] intentionally omitted <==

Research / Candidate Discovery & Optimisation

Toxicology - Enabling-toxicology

==> picture [248 x 66] intentionally omitted <==

----- Start of picture text -----

Research & Clinical Bioanalytics
- GLP & GCLP assays
----- End of picture text -----

Research External

TA Leaders & Teams

• Research Strategy

Innovation (REI)

• Project Portfolio

==> picture [191 x 70] intentionally omitted <==

----- Start of picture text -----

Haematology
----- End of picture text -----

==> picture [69 x 69] intentionally omitted <==

Functions / Capabilities

• Discovery Platforms

• Molecular Biology & Protein Engineering

• Cell Biology & Physiology

• In vivo Biology

• Translational Science

• Bioinformatics & Data Science

• etc.

Abbreviations: GLP – Good Laboratory Practice; GCLP – Good Clinical Laboratory Practice

15

CSL Behring Research – Strategy & Focus

TA Research Strategy

==> picture [363 x 274] intentionally omitted <==

----- Start of picture text -----

Therapeutic discovery
(internal & external)
Plasma
Extend existing
Research assets
Recombinant
MoA and LCM for clinical/
on market assets Proteins
Develop and expand
core platforms
Cell & Gene
Identify & validate external Therapy
clinical stage assets
----- End of picture text -----

Abbreviations: FIH – First-in-Human; MoA – Mechanism of Action; LCM – Life Cycle Management

• Lead strategically aligned discovery research through:

• Internal & external innovation

• External asset procurement

• Translate forward and reverse to better understand opportunities and reduce risk

• Accelerate discovery outcomes through to FIH

• Extend current Research assets for TA-aligned indications

• Develop and expand core platforms

• Drive clinical stage asset development including through MoA and LCM studies

==> picture [338 x 126] intentionally omitted <==

----- Start of picture text -----

Individual Therapeutic Area (TA)
Research Strategies
Immunology Haematology Respiratory Cardiovascular & Transplant
Metabolic
----- End of picture text -----

16

Development of Garadacimab for Progressive Fibrosing Interstitial Lung Disease (PF-ILD)/ Idiopathic Pulmonary Fibrosis (IPF) Role of FXII in Fibrogenesis

==> picture [888 x 325] intentionally omitted <==

----- Start of picture text -----

Hereditary M1 Macrophage
Angioedema M0 Macrophage
↑Vascular Permeability
Bradykinin
M2 Macrophage
↑M2 hyper-polarization
↑Coagulation/ wound
and pro-healing cytokines
clot formation and FXIIa- β
contact activation
IL-6
Fibroblast
Fibroblast
Fibrosis
----- End of picture text -----

==> picture [417 x 33] intentionally omitted <==

----- Start of picture text -----

 pro-inflammatory, pro-fibrotic, anti-fibrinolytic molecules,
proliferation, migration, wound scratch healing, chemotaxis
----- End of picture text -----

17

Development of Garadacimab for PF-ILD/IPF

Summary of Key Supportive Research Data

Clinical Data

• FXII increased in IPF lung tissues and in blood from patients with progressive IPF

Experimental Data

• Garadacimab inhibits FXIIa-β-induced fibrotic function of primary human lung fibroblasts

• FXIIa- b promotes fibrotic M2-type macrophages, reinforced by IL-6 → feedback loop

• Blocking FXIIa- b with 3F7* inhibits fibrosis in experimental mouse models:

• Lung, liver and renal fibrosis models

==> picture [49 x 49] intentionally omitted <==

Phase II – expected to commence H2 FY22

==> picture [296 x 282] intentionally omitted <==

----- Start of picture text -----

FXII Staining is Increased in PF-ILD
Lungs – Tissue Microarray
200


150
100
50
0
NDC IPF HP Sarc RA-ILDSSc-ILD
FXII (H-Score)
----- End of picture text -----*

• Parental Monoclonal Antibody (mAb) of Garadacimab

18

Research External Innovation & Collaboration Strategy The Competition for Innovation Parkville

==> picture [514 x 396] intentionally omitted <==

----- Start of picture text -----

Parkville
Bern
Marburg
Pasadena
King of Prussia
Global
Research site
locations
Seattle Children's
Research Inst.
Partnerships
ASLAN with Global funding
Kiniksa universities, & collaboration
Lassen MRIs, hospitals, initiatives
Denteric biotechs
WEHI CSL
Research
Pipeline
Partnerships
Scouting & with
disruptive incubators,
technology accelerators &
reviews venture
funders
Partnering
conference
attendance &
sponsorship
----- End of picture text -----

==> picture [108 x 67] intentionally omitted <==

==> picture [95 x 47] intentionally omitted <==

==> picture [87 x 57] intentionally omitted <==

==> picture [106 x 56] intentionally omitted <==

==> picture [105 x 37] intentionally omitted <==

==> picture [100 x 37] intentionally omitted <==

Abbreviations: MRI – Medical Research Institute

==> picture [90 x 91] intentionally omitted <==

19

Research External Innovation & Collaboration Strategy Centre for Biologic Therapies

==> picture [327 x 171] intentionally omitted <==

----- Start of picture text -----

Antibody genes
gIII gene
Human antibody Fab
Phage proteins
----- End of picture text -----

==> picture [161 x 68] intentionally omitted <==

----- Start of picture text -----

+
----- End of picture text -----

==> picture [156 x 57] intentionally omitted <==

• New jointly funded strategic initiative based in Parkville precinct

• Novel biological therapies for treatment of serious unmet medical need

• Translational / commercialisation opportunities for WEHI

• Potential new pipeline opportunities for CSL

• Address gap in biologics drug discovery in Australian medical research

• Develop Australian workforce expertise and career opportunities

WCSL129 αCOVID-19 mAb from CSL library*

• Source: Wheatley, A.K. et al ., (2021) Cell Reports 37, 109822; 1-26.

20

Gene Therapy Technologies

EtranaDez (Etranacogene dezaparvovec)

Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX in NHPs

==> picture [178 x 132] intentionally omitted <==

==> picture [178 x 134] intentionally omitted <==

==> picture [181 x 17] intentionally omitted <==

----- Start of picture text -----

AMT-060 5x10 [12] AMT-061 5x10 [12]
Wild-Type FIX Padua FIX
----- End of picture text -----

==> picture [160 x 98] intentionally omitted <==

Gene Therapies for Immune Deficiencies

==> picture [463 x 288] intentionally omitted <==

Source : Spronck, E.A. et al ., (2019) Mol. Ther. Meth. Clin. Dev. 13; P334-343.

21

Gene Therapy for Immune Deficiencies

• Agreement with Seattle Children’s Research Institute (SCRI) signed March 2020 (extended in April 2021 for Gene Editing)

• Preclinical expertise in lentiviral and gene-editing-based PID gene therapy (GT)

• Extensive clinical experience in ex vivo GT (>400 patients treated with CAR-T)

• Access to PID patients and patient samples

Platform

PIDs

Platform Technologies Ex Vivo HSC Gene Lentiviral Gene Therapy Therapy Platform Other Gene Editing Approaches

Wiskott- Aldrich Syndrome (WAS) X-linked Agammaglobulinemia (XLA) X-linked hyper IgM Syndrome (XHIM)

==> picture [160 x 98] intentionally omitted <==

==> picture [305 x 334] intentionally omitted <==

----- Start of picture text -----

Lentiviral-Based Gene Therapy
Functional gene
WAS
WAS
WAS
Defective gene
Hemopoietic Stem Cells Transduced Hemopoietic
Stem Cells
----- End of picture text -----

Abbreviations: PID – Primary Immune Deficiency; HSC – Hematopoietic Stem Cell

22

Gene Therapy for Immune Deficiencies

WAS Gene Therapy Program

• Mutation in gene that produces WAS protein (WASp)

• Incidence one in 100,000 male births per year (100-300pts/yr)

• Bleeding, eczema, and recurrent infections

==> picture [582 x 49] intentionally omitted <==

==> picture [49 x 49] intentionally omitted <==

Phase I/II – expected to commence H1 FY23

==> picture [160 x 98] intentionally omitted <==

Primary Immune Deficiencies*

==> picture [289 x 246] intentionally omitted <==

Source: Icahn School of Medicine at Mt Sinai Abbreviations: WAS – Wiskott- Aldrich Syndrome

23

==> picture [84 x 95] intentionally omitted <==

Biotech Out-Licensing & Partnering

24

ASLAN Pharmaceuticals - Atopic Dermatitis

==> picture [163 x 92] intentionally omitted <==

• In May 2019, CSL granted ASLAN full global rights to develop, manufacture and commercialise ASLAN004 (formerly CSL334) in all indications. CSL receives milestones and royalties

• ASLAN004 is a novel, first-in-class monoclonal antibody that targets the IL-13 receptor α1 subunit (IL-13Rα1), one of the components of Type 2 IL-4 / IL-13 receptor

• By blocking Type 2 receptors, ASLAN004 prevents signalling of both IL-4 and IL-13, key drivers of inflammation and central to triggering symptoms of allergy in atopic dermatitis

• Dupilumab / Dupixent targets Type I and Type II receptors to block both IL-4 and IL-13 activity - rate of dupilumab-associated ocular surface disease was 32%[1]

==> picture [586 x 87] intentionally omitted <==

----- Start of picture text -----

Program & Target Discovery Preclinical Phase I Phase II Anticipated Milestones
ASLAN004 Atopic Dermatitis (AD)
Initiate Phase IIb - 4Q 2021
Anti-IL-13Rα1 Asthma
----- End of picture text -----*

*second indication to be confirmed

1 Popiela, M.Z. et al., (2021) Eye; https://doi.org/10.1038/s41433-020-01379-9

25

ASLAN Pharmaceuticals - Atopic Dermatitis

==> picture [163 x 92] intentionally omitted <==

Phase I MAD Study (ASLAN004)

• Moderate-to-severe atopic dermatitis patients (n=50)

• 200mg, 400mg and 600mg weekly

• ASLAN004 n=6, placebo n=2 per cohort

• Expansion cohort 600mg weekly, ASLAN004 n>18, placebo n>9

• Primary endpoint – safety and tolerability

• Secondary end point – clinical efficacy as measured by % change in Eczema Area Severity Index (EASI)

Endpoint (8 weeks)	RITT (n=29)	RITT (n=29)	RITT (n=29)
	600mg (n=16)	Placebo (n=13)	p-value1
Mean % change from baseline in EASI	-64.9	-27.2	0.021
EASI-50 (%)	81.3	30.8	0.008
EASI-75 (%)	68.8	15.4	0.005
EASI-90 (%)	37.5	15.4	0.183
IGA 0/1 (%)	43.8	15.4	0.107
Mean % change from baseline in peak pruritus Numerical Rating Scale	-38.6	-15.3	0.051
Mean change from baseline in POEM	-9.8	-2.5	0.007

• Proportion of patients with adverse events and treatment‐related adverse events were similar across treatment and placebo arms

==> picture [49 x 49] intentionally omitted <==

Phase II – initiating 4Q 2021

• No incidences of conjunctivitis in expansion cohort

• 1 One-sided p-value. Study powered to assess statistical significance in primary efficacy endpoint at one-sided 5% level. Abbreviations: MAD – Multiple Ascending Dose; IGA – Investigator’s Global Assessment; POEM – Patient-Oriented Eczema Measure; RITT – Revised Intent to Treat

26

Kiniksa - Giant Cell Arteritis (GCA) and COVID

==> picture [105 x 74] intentionally omitted <==

• In Dec 2017, AstraZeneca / CSL granted Kiniksa full global rights to develop, manufacture and commercialise Mavrilimumab in all indications. CSL receives milestones and royalties

• Mavrilimumab targets GM-CSF receptor and inhibits action of GM-CSF, a key mediator in inflammation and autoimmune disease

• Positive data reported from Phase II trial of Mavrilimumab in GCA, a chronic inflammatory disease of medium-large arteries (75,000- 150,000 cases estimated in US)

• Reduced need for mechanical ventilation and improved survival reported for Mavrilimumab (compared to placebo) in Phase II portion of Phase II/III clinical trial in patients with COVID-19-related ARDS; enrolment ongoing[1]

Program & Target	Preclinical	Phase I	Phase II	Phase III
Mavrilimumab Anti-GM-CSFRα	COVID-19 Pneumonia Giant Cell Arteritis
		& Hyperinflammation

1 Pupim, L. et al., (2021) Ann. Rheum Dis 80(1); 198-199. Abbreviations: ARDS – Acute Respiratory Disease Syndrome

27

Kiniksa - Giant Cell Arteritis (GCA) and COVID

==> picture [105 x 74] intentionally omitted <==

Phase II Study - GCA

• Active biopsy- or imaging-proven new onset or relapsed refractory GCA

• n=70; 35 NO and 35 R/R

• 150mg q2wk for 26 wks, Mavri:placebo 3:2

• 26 week steroid taper

• Primary endpoint – time to first adjudicated flare

• Secondary endpoint – sustained remission through week 26

==> picture [49 x 49] intentionally omitted <==

Phase III – ongoing

Mavrilimumab reduces risk of flare and increases sustained remission in patients with GCA[1]

==> picture [497 x 254] intentionally omitted <==

----- Start of picture text -----

100
80
Mavrilimumab
Placebo
60
40
Mavrilimumab Placebo
(n=42) (n=28)
20
Patients with Flare
8 (19) 13 (46.4)
by Week 26, n (%)
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
Time from Randomization (Weeks)
Probability of
Sustained Remission (%)
----- End of picture text -----

1 Cid, M.C. et al., (2021) Ann. Rheum Dis 80(1); 31-32

• Abbreviations: NO – New Onset; R/R – Relapsing/ Refractory; q2wk – every 2 weeks

28

CSL Behring Research

Creating and progressing a sustainable portfolio of early stage opportunities

• Continuing to innovate in areas of business strength

• Developing new opportunities in areas of unmet need

Three drug discovery platforms applied across five TAs

• Leveraging in-house technologies to support external innovation

• Expanding capacity and capability across global Research sites Continued investment in external innovation

==> picture [375 x 170] intentionally omitted <==

• From venture capital investment to long term strategic collaborations

29

==> picture [55 x 99] intentionally omitted <==

Development Deirdre BeVard Senior Vice President, R&D Strategic Operations CSL Behring

==> picture [109 x 9] intentionally omitted <==

==> picture [88 x 131] intentionally omitted <==

==> picture [35 x 19] intentionally omitted <==

30

CSL112 Apolipoprotein A-I (human) - AEGIS-II

• Managing recruitment through COVID-19 impact on sites and patients

• 2[nd] futility analysis in 2021 passed

• 3[rd] interim analysis – end FY22

==> picture [635 x 196] intentionally omitted <==

----- Start of picture text -----

1 ° Endpoint : MACE MACE Follow Up
D90 D180 D365
>17,000
Acute 6g CSL112
Myocardial Screening Randomisation
Placebo
Infarction
(AMI)
Phase III – ongoing
----- End of picture text -----

==> picture [114 x 114] intentionally omitted <==

==> picture [255 x 174] intentionally omitted <==

----- Start of picture text -----

CSL112
particles
ABCA1
Intracellular transporter
cholesterol
----- End of picture text -----

31

Haematology

EtranaDez

Gene Therapy (AAV5-Padua FIX) for Treatment of Haemophilia B

• CSL acquired exclusive global rights to commercialise EtranaDez from uniQure in May 2021

• Clinical program includes:

• Phase IIb study: Open-label, single-dose, single-arm trial, using Padua FIX, in adult males with severe or moderately severe Haemophilia B (HB)

• Phase III HOPE-B study: Open-label, single-dose, single-arm, trial in adult males with severe or moderately severe HB (FIX ≤ 2%) on routine FIX prophylaxis and with/without pre-existing neutralizing antibodies (nAbs) to AAV5

• BLA/MAA submissions – H2 FY22

Abbreviations: AAV5 - Adeno-Associated Virus serotype 5; BLA – Biologic Licence Application; MAA – Market Authorisation Application

32

EtranaDez – HOPE-B Study 12 Month Data

Haematology

==> picture [231 x 13] intentionally omitted <==

----- Start of picture text -----

Endogenous FIX Activity over 52 weeks [1]
----- End of picture text -----

• FIX activity increased rapidly to mid- to normal range with mean of 41.5 IU/dL (±21.7; 5.9, 113.0) at Wk 52[1]

• FIX activity similar (~44%) in participants with and without pre-existing nAbs to AAV5[1]

• 96% of patients discontinued prophylaxis[1]

• Mean FIX activity Ph IIb patients stable and durable at 2.5 years[2]

• Phase III preliminary data translates into meaningful clinical response with reduction in Annualised Bleeding Rates (ABR)

• Majority of patients did not report any bleeding during 52 weeks after dosing[1]

• 1 Pipe. S.W. et al ., (2021) ISTH, PB0653

==> picture [338 x 166] intentionally omitted <==

Adjusted Annualized Bleeding Rates (ABR) in the First 12 months Post-treatment[1]

==> picture [372 x 97] intentionally omitted <==

• 2 Gomez, E. et al ., (2021) ISTH, LPB0020

• Abbreviations: AAV5 - Adeno-Associated Virus serotype 5

33

Ongoing New Investigations with Hizentra[®]

==> picture [114 x 114] intentionally omitted <==

Systemic Sclerosis (SSc)

Dermatomyositis (DM)

A rare, heterogeneous, multi-systemic, progressive autoimmune disease with significant morbidity

A severe inflammatory autoimmune disease that leads to muscle weakness and skin changes with high comorbidity

• Incidence: 0.8 – 5.6 per 100,000[1]

• Prevalence rate: 3.8 – 34.1 per 100,000[1]

• 3-4 times more common in females than males[2]

• Incidence 11 per 1,000,000

• Prevalence rate 14 per 100,000

• Increases with age (peak ages 70-79)[3]

Presents with hardening of skin, inflammation and scarring of internal organs, endothelial injury leading to microangiopathy and dysregulation of autoimmunity

The disease can also affect other organs such as lungs, heart and the esophagus and in general is associated with a higher rate of malignancy (cancer)

Highest mortality among systemic autoimmune diseases

No treatment currently addresses all of the multi-system impact

Mortality rate: 10-30% (5y), high comorbidity

High unmet need for long-term treatments without systemic side effects

• 1 Varga, J. (2020) In J.S. Axford (Ed.), UptoDate, Accessed June 1, 2021.

2 National Organization for Rare Diseases. Scleroderma. Accessed June 4, 2021.

• 3 Svensson J. (2017) Clin Exp Rheumatol . 35(3):512-515

34

Hizentra[® ] SSc - SURPASS

Phase II Safety and Bioavailability Study of Hizentra[®] in Adults with Systemic Sclerosis (SSc)

==> picture [114 x 114] intentionally omitted <==

• Study fully enrolled ahead of schedule

• Anticipated study completion 2022

==> picture [768 x 233] intentionally omitted <==

----- Start of picture text -----

Patients with diffuse
16 weeks 16 weeks
cutaneous SSc (n=26)
Hizentra [®] Privigen [®]
Privigen [®] Hizentra [®]
Phase II – ongoing
Screening
Randomisation
----- End of picture text -----

==> picture [43 x 128] intentionally omitted <==

----- Start of picture text -----

Safety Follow-up
----- End of picture text -----

35

Hizentra[® ] DM - RECLAIIM

Phase III Study of Hizentra[®] in Adults with Dermatomyositis

==> picture [114 x 114] intentionally omitted <==

Weeks 1-53

==> picture [805 x 294] intentionally omitted <==

----- Start of picture text -----

Active DM with/without
Muscle Weakness
Hizentra [®] 0.5g/kg Hizentra [®] 0.5g/kg
Placebo Hizentra [®] 0.5g/kg
Weeks 1-25 Weeks 25-53
Primary Endpoint:
Total Improvement Score
Responder Status
Phase III – ongoing
Long-term Follow-up
Screening
Randomisation
----- End of picture text -----

36

Hereditary Angioedema (HAE)

Autosomal dominant genetic condition

1 in 10,000 – 50,000 people

Unregulated protein cascade

→ elevated levels of bradykinin

→ fluid release into tissues

→ swelling in specific parts of body

==> picture [160 x 213] intentionally omitted <==

Normal appearance

==> picture [160 x 213] intentionally omitted <==

During cutaneous attack

Unpredictable onset, severity and attack location, lasts for 2-5 days

37

Garadacimab – A First-in-Class, Fully Human mAb that Inhibits FXIIa to Treat HAE

==> picture [114 x 114] intentionally omitted <==

Monthly SC Garadacimab Markedly Reduces Mean HAE Attack Rate (Phase II Study Results)

==> picture [738 x 252] intentionally omitted <==

----- Start of picture text -----

5
4.24
(2.74–5.75)
88.68% 98.94% 90.50%
4 Mean Reduction Mean Reduction Mean Reduction
3
Mean Reduction in HAE Attacks per Month vs Placebo
2
0.48
1 0.40
(-0.33–1.29) 0.05
(-0.07–0.88)
(-0.06–0.15)
0
Garadacimab 75 mg Garadacimab 200 mg Garadacimab 600 mg Placebo
q4w (n=9) q4w (n=8) q4w (n=7) q4w (n=8)
Mean Number of HAE Attacks/Month
----- End of picture text -----*

Source: Craig, T., (2020) European Academy of Allergy and Clinical Immunology Congress

38

Garadacimab - CSL’s First mAb in Phase III

==> picture [261 x 68] intentionally omitted <==

==> picture [114 x 114] intentionally omitted <==

==> picture [846 x 272] intentionally omitted <==

----- Start of picture text -----

Phase III
Phase I
Efficacy, Safety, PK/PD
Phase II
Safety, PK
Efficacy, Safety, PK/PD Double-blind, Placebo-controlled
3 doses &
placebo tested Phase III
Phase I
Safety Extension
Safety, PK
Including Phase II, Phase III & Naive Patients
Completed Completed Ongoing Ongoing
Healthy ~40 HAE patients ~60 HAE patients ~150 HAE patients
Broad dose range POC Pivotal, Confirmatory Long term safety
IV & SC Dose selection, Efficacy, Safety, Efficacy, PK/PD, QoL
Safety, PK/PD PK/PD, QoL
----- End of picture text -----

Abbreviations: PK - Pharmacokinetic; PD – Pharmacodynamic; POC – Proof of Concept; QoL – Quality of Life

==> picture [49 x 49] intentionally omitted <==

Global submission targeted 2023

39

Comparable Efficacy of HAEGARDA[®] for HAE in Japanese Patients

==> picture [114 x 114] intentionally omitted <==

Global Phase III Pivotal Study

Japan Phase III Study

==> picture [359 x 311] intentionally omitted <==

----- Start of picture text -----

Median Number of Attacks/month
4
3 3.8 95%
2
1 0.3
0
Placebo (n=42) CSL830 (n=43)
Study Group
Percentage of Patients with ≥50% Attack Reduction
120%
90%
82.5%
80%
57.5%
40%
40%
0%
≥ 50% ≥ 70% ≥ 90% ≥ 100%
% of Attack Reduction
No. of attacks
% of patients
----- End of picture text -----

==> picture [360 x 311] intentionally omitted <==

----- Start of picture text -----

Median Number of Attacks/month
4
3 3.6
100%
2
1
0
0
Run-in (n=9) CSL830 (n=9)
Study Group
Percentage of Patients with ≥50% Attack Reduction
120%
100%
77.8%
80% 66.7% 66.7%
40%
0%
≥ 50% ≥ 70% ≥ 90% ≥ 100%
% of Attack Reduction
No. of attacks
% of patients
----- End of picture text -----

40

Progress Across All of our TAs and Scientific Platforms

• Our scientists continue to grow our pipeline through internal discovery and external collaborations

• Our focus drives continued progress in the Phase II and Phase III portfolio

• Our innovation in other novel mAbs – CSL324, CSL311, CSL346 and Clazakizumab and other novel plasma proteins – CSL889 (Hemopexin) and CSL787 (Nebulised Ig) continues to progress well

• Our patient focus leads to optimisation and expansion of Established Products with new indications and markets

==> picture [494 x 145] intentionally omitted <==

----- Start of picture text -----

Haematology
----- End of picture text -----

41

CSL R&D - Together We Deliver on our Promise to Patients

==> picture [165 x 106] intentionally omitted <==

==> picture [111 x 73] intentionally omitted <==

==> picture [163 x 107] intentionally omitted <==

==> picture [76 x 112] intentionally omitted <==

==> picture [143 x 93] intentionally omitted <==

==> picture [120 x 79] intentionally omitted <==

==> picture [174 x 114] intentionally omitted <==

==> picture [109 x 160] intentionally omitted <==

==> picture [117 x 76] intentionally omitted <==

==> picture [129 x 85] intentionally omitted <==

==> picture [163 x 107] intentionally omitted <==

==> picture [151 x 99] intentionally omitted <==

==> picture [103 x 152] intentionally omitted <==

==> picture [130 x 85] intentionally omitted <==

==> picture [139 x 91] intentionally omitted <==

==> picture [127 x 84] intentionally omitted <==

==> picture [129 x 85] intentionally omitted <==

42

==> picture [55 x 99] intentionally omitted <==

Commercial Bill Campbell Executive Vice President and Chief Commercial Officer CSL Behring

Zahra: living with Hereditary Angioedema (HAE).

==> picture [109 x 9] intentionally omitted <==

==> picture [35 x 19] intentionally omitted <==

43

CSL Behring FY21

Performance

==> picture [67 x 59] intentionally omitted <==

• Global revenue of $8,574M/+6%[1]

Commercial Highlights

==> picture [483 x 220] intentionally omitted <==

----- Start of picture text -----

$388
$1,770
Ig
Albumin Revenue
Haemophilia US $8,574M $4,238
Specialty 6% [1]
$1,107
Other [2]
$1,071
----- End of picture text -----

Immunology

• Underlying Ig demand remained strong through pandemic

• ▪ 15% Hizentra[®] revenue growth; continued success in CIDP

Albumin

==> picture [51 x 50] intentionally omitted <==

==> picture [67 x 58] intentionally omitted <==

• Sales normalized in China under new GSP

• Significant contribution to FY21 YoY growth

Haemophilia

==> picture [67 x 59] intentionally omitted <==

• Maintained IDELVION[®] leadership in key markets[3]

Source:

• 1 Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance.

• 2 Includes HPV royalties & Ig Hyperimmunes

• 3 Data on file

• Abbreviations: CIDP - Chronic inflammatory demyelinating polyneuropathy; FFP - Fresh Frozen Plasma; GSP – Good Supply Practices; YoY – Year on Year

==> picture [66 x 59] intentionally omitted <==

Specialty

• Strong growth from HAEGARDA[®] and KCENTRA[®]

• HAEGARDA[®] most patients since launch; 14% revenue growth

• KCENTRA[®] continued penetration vs FFP

44

Targeted Protein Therapeutic Market Continues to Grow

==> picture [772 x 356] intentionally omitted <==

----- Start of picture text -----

2016 2021
Albumin
$4.2B
Albumin
Immunoglobulins
5-Year CAGR:
$3.8B
$15.8B
Immunoglobulins
Total Market: 6%
$9.0B
Ig: 12%
Total Global Total Global
Market Value
Market Value
Specialty: 8%
~$27.0B Haemophilia
~$36.8B
$11.7B
Haemophilia: 2%
Haemophilia Specialty
Albumin: 2%
$10.8B $3.4B
Specialty
$5.1B
----- End of picture text -----

Source: Company 3Q 2016 reports/financial schedule; MRB global Coagulation Factors Concentrate Market 2015 & 201; MRB WW Plasma Fractionation Market 2015 interim report; CSL Actuals FY16

Source: Analyst Reports; Company Annual Reports; Data on file; CSL Actuals FY21; Immunoglobulins market include Hyperimmunes; Haemophilia market include Factor XIII and non-factor; Specialty includes AAT, HAE, Fibrinogen, PCC, ATT markets

45

Immunoglobulin Market

Market Dynamics

• COVID-19: Industry-wide impact on plasma collection

• Underlying demand remains strong

• Significant patient needs in PID & CIDP

• Expanding usage for SID

• Shifting preference to SCIg and home administration

Global Ig Volume by Indication

==> picture [254 x 267] intentionally omitted <==

----- Start of picture text -----

Other PID
23%
25%
MG $15.8B
5%
ITP
6% SID
20%
CIDP
22%
----- End of picture text -----

Source: Data on file for 2020

Abbreviations: CIDP - Chronic inflammatory demyelinating polyneuropathy; ITP - Idiopathic thrombocytopenic purpura; MG – Myasthenia Gravis; PID – Primary Immune Deficiency; SID –Secondary Immune Deficiency

46

==> picture [251 x 167] intentionally omitted <==

==> picture [111 x 59] intentionally omitted <==

▪ Hizentra[®] +15% revenue growth[2] ; remains the clear SCIg market leader

• Increased preference for at-home treatment

==> picture [169 x 55] intentionally omitted <==

• Supply tightness intensified by COVID-19

• Privigen[®] volume impacted by shift to Hizentra[®]

• Continued uptake in CIDP

Immunoglobulins

FY21 Sales: $4,238M[1]

==> picture [252 x 59] intentionally omitted <==

----- Start of picture text -----

Up 3% [2]
----- End of picture text -----

• Christal: living with chronic inflammatory demyelinating polyneuropathy (CIDP)

1 Excludes Ig hyperimmunes

• 2 Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance.

• 3 CSL Internal Data

• Global demand remains strong in core indications

• Recent Medicare Part B reimbursement approval

US Ig Volume Mix Evolution[3]

==> picture [407 x 176] intentionally omitted <==

----- Start of picture text -----

100% 1% 0% 0%
13% 10%
80%
68% 67% 63%
60% 61% 64%
40%
20% 27% 27% 31% 33% 37%
0%
FY17 FY18 FY19 FY20 FY21
Hizentra® Privigen® Carimune®
----- End of picture text -----

47

==> picture [172 x 157] intentionally omitted <==

==> picture [164 x 146] intentionally omitted <==

Hizentra®

==> picture [185 x 127] intentionally omitted <==

==> picture [48 x 42] intentionally omitted <==

Reasons for IVIg to Hizentra[®] Switch[1]

• 1 Ig used worldwide for PID[1] and the only SCIg approved for use in CIDP

Need more flexibility/time 39%

Having problem finding a vein 30%

• Proven long-term protection with over 3.5 years of clinical evidence and 10+ years of real-world experience

Impossibility of getting to the infusion 26% center due to COVID-19

Difficulty getting to IV infusion centers 22%

• Continue to lead within SCIg as we bring more innovative and personalized treatment options to patients

“ Covid has impacted thinking - At this point, after seeing what has happened …, we really need to try to transition these patients to something that’s going to be more manageable if there’s ever something like this again.” – Lisa 48 , Neurologist | Confidential – Internal Use Only

1 Data on file

Hizentra[®] - Continued Strong Performance

==> picture [111 x 59] intentionally omitted <==

Robust SCIg Market Growth of 13.1% During Same Period

==> picture [774 x 288] intentionally omitted <==

----- Start of picture text -----

80%
70%
59% 60% 61% 60% 60% 60% 61% 60% 61% 61% 60%
57% 58% 57%
60%
50%
40%
30%
20%
10%
0%
Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21
®
Hizentra (CSLB) Competitor A Competitor B Competitor C Competitor D Competitor E
----- End of picture text -----

Source: Data on file 7MM refers to US, DE, FR, IT, UK, ES & JP

49

CIDP Patients Benefitting From Hizentra[®] Across the Globe

==> picture [111 x 59] intentionally omitted <==

Total Hizentra[®] CIDP Patients by Region[1,2]

NA EU APAC ICO

1[st] Approvals (US/EU)

1 Countries Included – JP, AT, IT, NL, SK, UK, IS, CH, US, GER, GR, DE.

2 Data on file

50

==> picture [251 x 167] intentionally omitted <==

Haemophilia

FY21 Sales: $1,107M

Down 4%[1]

==> picture [118 x 51] intentionally omitted <==

IDELVION[®]

• Standard of care for Haemophilia B

▪ Maintained leadership[2] in several key markets, including US, Germany, Italy, Switzerland & Japan

==> picture [89 x 54] intentionally omitted <==

==> picture [96 x 55] intentionally omitted <==

==> picture [99 x 47] intentionally omitted <==

AFSTYLA[®]

• Impacted by competitive market & reduced doctor visits during COVID-19

pdFVIII

▪ Maintained market leadership globally in vWD with 56% patient share[2,3]

==> picture [252 x 45] intentionally omitted <==

Logan: living with Haemophilia B.

▪ Recent strong launches in France, Spain and Taiwan

HUMATE[®]

▪ Strong revenue growth of 13%[1] in the US

1 Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance.

• 2 Data on file

• 3 Includes HUMATE®/HAEMATE® and VONCENTO®

Abbreviations: vWD – von Willebrand Disease

51

IDELVION[® ] - Maintaining Market Leadership

==> picture [122 x 52] intentionally omitted <==

==> picture [794 x 310] intentionally omitted <==

----- Start of picture text -----

70%
60%
50%
45%
42% 43% 43% 43% 44% 44% 44%
41%
40%
39%
38%
40% 36%
34%
30% 30%
27%
22%
20%
19%
14%
10%
8%
3%
0% 0%
Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21
IDELVION Idelvion [®] Competitor A Competitor B All Other
rFIX Prophylaxis Patient Share
----- End of picture text -----

Based on data from US, JP, DE, IT, ES, CH and UK where IDELVION[®] is reimbursed and commercially available. Source: Data on file

52

IDELVION[®] - Market Shares Within Key Markets

==> picture [122 x 52] intentionally omitted <==

IDELVION[®] rFIX Prophylaxis Patient Share by Country

Germany Italy Japan Spain Switzerland UK US Launched Markets Average

==> picture [776 x 256] intentionally omitted <==

----- Start of picture text -----

70% 62%
60% 61%
57%
50%
45%
40% 44%
42%
30%
41%
20%
28%
10%
0%
Market Share (Patient) %
Q1-16 Q2-16 Q3-16 Q4-16 Q1-17 Q2-17 Q3-17 Q4-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21
----- End of picture text -----

Source: Data on file

53

AFSTYLA[® ] - Market Shares Within Key Markets

==> picture [106 x 61] intentionally omitted <==

AFSTYLA[®] rFVIII Prophylaxis Patient Share by Country

==> picture [774 x 315] intentionally omitted <==

----- Start of picture text -----

France Germany Italy Japan Spain Switzerland US Launched Markets Average
12%
10% 9%
9%
8%
6% 5%
5%
4% 4%
3%
2% 2%
1%
0%
Market Share (%)
Q1-16 Q2-16 Q3-16 Q4-16 Q1-17 Q2-17 Q3-17 Q4-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21
----- End of picture text -----

Source: Data on file

54

55

==> picture [248 x 177] intentionally omitted <==

Specialty Products

FY21 Sales: $1,770M

Up 2%[1]

==> picture [252 x 45] intentionally omitted <==

Cheryl: living with Hereditary Angioedema (HAE).

• 1 Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance.

==> picture [253 x 82] intentionally omitted <==

==> picture [134 x 44] intentionally omitted <==

KCENTRA[®]

• HAEGARDA[® ] / Berinert SC[®]

• ▪ Remains the gold standard for ▪ Offers best in class efficacy[3]

• warfarin reversal in the US ▪ US: Most patients since launch

▪ ▪ Substantial growth opportunities, Treatment paradigm further with FFP still used in ~40% of shifts from on-demand to longpatients[2 ] in the US term prophylaxis

Respreeza[®] / Zemaira[®]

▪ ▪ Demand rebounded to pre-COVID Investing to enhance supply chain levels in the US & ensure future supply

• 2 Data on file

• 3 In the clinical trial, 95% median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA[®] vs placebo, and a >99% median reduction in rescue medication use in patients receiving 60 IU/kg of HAEGARDA[®] vs placebo.

56

==> picture [145 x 47] intentionally omitted <==

KCENTRA[® ] Growth in US

• KCENTRA[®] remains first and only FDA approved 4FPCC for reversing patients on warfarin

• KCENTRA[®] is supported by multiple clinical guidelines as the preferred reversal agent[1]

• ~1.7M patients on warfarin, with ~25k new patient starts per month[2]

• KCENTRA[®] growth driven by:

• Superior efficacy data versus fresh frozen plasma

• Penetration within existing large hospital systems

• Innovative digital promotion and education programs

• 1 Neurocritical Care Society; Society of Critical Care Medicine; American College of Cardiology; American College of Chest Physicians; American Society of Gastrointestinal Endoscopy; American College of Surgeons

• 2 Data on file – represents US market only

Warfarin Urgent/Major Bleed Reversal Shares

==> picture [412 x 435] intentionally omitted <==

----- Start of picture text -----

80%
70%
60%
50%
40%
30%
20%
10%
0%
®
KCENTRA FFP Others
KCENTRA [®] Demand
Demand Units (IU/Millions)
FY15 FY16 FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

57

HAEGARDA[®] /Berinert[®] SC

Growth in the Face of Competition

==> picture [100 x 49] intentionally omitted <==

==> picture [104 x 36] intentionally omitted <==

Regional Progress

• US: Most patients since launch

Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 HAEGARDA /Berinert SC Patients ® ® 1

• EU/AU: New launches exceeding expectations

• Spain achieved 55% patient share[1,2] within a year of launch

• Five additional launches planned by end of 2022

2 Patient share in the non-steroidal prophylaxis segment

1 Data on file

58

HAEGARDA[®] /Berinert[®] SC Growth Potential

==> picture [100 x 49] intentionally omitted <==

==> picture [104 x 36] intentionally omitted <==

==> picture [402 x 256] intentionally omitted <==

----- Start of picture text -----

HAE Market Share (Patients) by Regimen [1]
On-Demand Prophylaxis
100%
80%
60%
40%
20%
0%
2017 2018 2019 2020
27% 29%
34%
39%
73% 71% 66%
61%
Market Share (Patients) %
----- End of picture text -----

• Prophylaxis segment continues to grow but ~60% of patients still on acute therapy

▪ HAEGARDA[®] /Berinert[®] SC has proven record of high efficacy and safety[2]

• Continue to see patients switch back from competing products to the benefits of HAEGARDA[®] /Berinert[®] SC[1]

. Efficacy ultimately drives patient preference Patients define convenience as being free from attacks, not just frequency and ease of administration[3] . Prophylaxis treatment with HAEGARDA® /Berinert® SC addresses this need.

• 1 Data on file – Represents US, DE & ES. Includes all HAE markets, split on long term prophylaxis vs. on-demand

• 2 In the clinical trial, 95% median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA® vs placebo, and a >99% median reduction in rescue medication use in patients receiving 60 IU/kg of HAEGARDA[®] vs placebo.

• 3 Per 2020 Harris Poll

59

New Products Contributing Significantly to Growth[1]

==> picture [819 x 325] intentionally omitted <==

----- Start of picture text -----

CAGR
$2,000
CAGR = 86%
3
$1,691 CIDP 75% [4]
$1,524
$1,500 3
CIDP 21% [4]
$1,203
$1,000
30% [4]
$798
$500 76%
$140
44%
$-
FY17 Act FY18 Act FY19 Act FY20 Act FY21 Act
2
CSLB New Products
Revenue ($M)
----- End of picture text -----

1 Revenues shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance.

2 CSLB New Products include Hizentra® CIDP, Privigen® CIDP, HAEGARDA® /Berinert® SC, AFSTYLA® & IDELVION®

3 CIDP revenue represents markets where the indication was recently acquired

4 CAGR calculated off base of FY18 when launch occurred

60

Commercial Summary

==> picture [67 x 67] intentionally omitted <==

Executing on strategies

==> picture [61 x 61] intentionally omitted <==

COVID restrained commercial activity

==> picture [61 x 61] intentionally omitted <==

New products contributing significantly to growth

==> picture [69 x 69] intentionally omitted <==

Strong underlying demand across the portfolio

==> picture [63 x 63] intentionally omitted <==

Balanced regional & key market growth

==> picture [65 x 65] intentionally omitted <==

Robust new product pipeline to fuel growth

| Confidential – Internal Use Only

61

==> picture [55 x 99] intentionally omitted <==

SEQIRUS Russell Basser MD Senior Vice President, R&D Ethan Settembre PhD Vice President, Research

==> picture [109 x 9] intentionally omitted <==

==> picture [103 x 115] intentionally omitted <==

==> picture [104 x 108] intentionally omitted <==

==> picture [35 x 19] intentionally omitted <==

62

Population Protection Through Innovation

==> picture [693 x 393] intentionally omitted <==

----- Start of picture text -----

sa-
mRNA
aQIVc
aH5N1c
QIVc
Designed for adults 65 years and older
aTIV/
aQIV
aH5N1
QIVe
TIV
----- End of picture text -----

63

Seqirus Milestones in FY21 & FY22 (to date)

FLUCELVAX[®] QUAD

• Paediatric efficacy study (2-17yrs) – published in New England Journal of Medicine - 14 Oct 2021

• US 6mo+ age extension approval

• Regulatory approvals – 2yr+ in US/EU/UK/CA, 9yr+ in AU (5 further regulatory approval submissions)

• Paediatric immunogenicity (6mo-4yr) – met all endpoints

FLUAD[®] QUAD

• UK, NZ approval for 65yrs+ (2 further regulatory approval submissions)

aQIVc

• Phase II clinical trial standard dose completed

==> picture [249 x 45] intentionally omitted <==

==> picture [419 x 229] intentionally omitted <==

• Phase II clinical trial dose ranging study completed recruitment

64

New Cell Culture Facility in Australia

Tullamarine, Victoria

• Under construction – open in 2026

• A$800m capital investment from Seqirus

• Commercial export manufacturing facility

• Next-generation, cell-based seasonal influenza vaccines

• A$800m/10 year supply agreement with Commonwealth for antivenoms, Q-fever vaccines, pandemic influenza vaccines

==> picture [458 x 245] intentionally omitted <==

65

Collaboration with BARDA

Biomedical Advanced Research and Development Authority

==> picture [114 x 114] intentionally omitted <==

Agreement to develop and evaluate 2 influenza A virus (H2Nx) vaccine candidates to support pandemic preparedness

1. Adjuvanted (MF59[®] ) and cell-based based technologies

2. Self-amplifying mRNA (sa-mRNA) platform

US$35M multi-year contract extends to clinical proof of concept early trials

66

Impact of COVID-19 on Influenza and Vaccination

Suppression of circulating influenza virus so far but ongoing concerns on potential of “twindemic”

• low level circulation

• bird and animal reservoirs remain

Strong demand for influenza vaccine – increased doses and differentiated products

==> picture [386 x 212] intentionally omitted <==

----- Start of picture text -----

Number of doses of influenza vaccine distributed
2018-21
Total
North America
ROW
0 20 40 60 80 100 120 140
Millions
FY21 FY20 FY19 FY18
----- End of picture text -----

==> picture [323 x 200] intentionally omitted <==

----- Start of picture text -----

50
40
30
20
10
0
FY18 FY19 FY20 FY21
Afluria Flucelvax Fluad
Millions
----- End of picture text -----

67

Real World Evidence – Consistent Benefit of MF59[® ] Adjuvant and Cell Technology over Multiple Seasons

Fluad[®] (3 strain) – Benefit of MF59[®]

Flucelvax[®] - Benefit of Cell Culture

Comparator Study Season Outcome*						% rVE (95%CI)	% rVE (95%CI)
TIV Boikos (2020) 2017/18 Hospitalized or ED/GP							8 (4, 10)
TIV Pelton (2020) 2017/18 Hospitalized or ED							11 (2, 19)
TIV Pelton (2020) 2017/18 GP							25 (17 32)
TIV Boikos (2020) 2018/19 Hospitalized or ED/GP							, 26 (18, 32)
QIV Boikos (2020) 2017/18 Hospitalized or ED/GP QIV Pelton (2020) 2017/18 Hospitalized or ED QIV Pelton (2020) 2017/18 GP QIV Boikos (2020) 2018/19 Hospitalized or ED/GP QIV CORE 2021 2019/20 Hospitalized or ED/GP							18 (16, 21) 9 (1, 16) 36 (31, 41) 28 (26, 30) 28 (24, 31)
HD-TIV Boikos (2020) 2017/18 Hospitalized or ED/GP							8 (2, 13)
HD-TIV Pelton (2020) 2017/18 Hospitalized or ED							3 (-3, 9)
HD-TIV Pelton (2020) 2017/18 GP							17 (11, 22)
HD-TIV Boikos (2020) 2018/19 Hospitalized or ED/GP							7 (3, 11)
HD-TIV Pelton (2021) 2018/19 Hospitalized or ED							7 (3, 10)
HD-TIV Pelton (2021) 2018/19 GP							2 (-4, 7)
HD-TIV CORE 2021 2019/20 Hospitalized or ED/GP							14 (11, 17)
HD-TIV HEOR 2021 2019/20 Hospitalized or ED							3 (-3, 9)
-10 Favours Comparator			10 30 50 FavoursFLUAD®

Comparator Study Season Age Group Outcome*	Comparator Study Season Age Group Outcome*			% rVE (95%CI)
QIV Boikos (2020) 2017/18 ≥4 GP				36 (26, 45)
QIV Divino (2020) 2017/18 4-64 Hospitalization				14 (9, 20)
QIV Boikos (2021) 2018/19 ≥4 Hospitalized or ED/GP				8 (7, 9)
QIV Krishnarajah (2021) 2018/19 4-64 Hospitalization				7 (0.1, 13)
QIV CORE (2021) 2019/20 ≥4 Hospitalized or ED/GP				17 (16, 19)
QIV HEOR (2021) 2019/20 4-64 Hospitalization				5 (1, 10)
-10 Favours Comparator			10 30 50 FavoursFLUCELVAX®

*Outcomes due to influenza or pneumonia

2017/18 was the first season a cell-based seed (H3N2) was included in FLUCELVAX[®]

Boikos, C. et al ., (2020) CID 73:816-823 Pelton, S.I. et al. , (2020) Vaccines 8:446

Pelton, S.I. et al., (2021) Vaccine 39:2396-2407

CORE (2021): Presented at ECCMID 2021, manuscript pending HEOR (2021): Manuscript pending

Abbreviations: CI - Confidence Interval; ED - Emergency Department; GP - General Practitioner; (r)VE - (relative) Vaccine Effectiveness; TIV /QIV – standard dose Trivalent/ Quadrivalent Vaccine; HD - High Dose

68

CSL Strengths Applied to COVID-19

==> picture [220 x 110] intentionally omitted <==

----- Start of picture text -----

+
----- End of picture text -----

==> picture [146 x 123] intentionally omitted <==

----- Start of picture text -----

S-protein
----- End of picture text -----

University of Queensland

(V451)

Recombinant S-clamp protein MF59[®] adjuvant

AstraZeneca (AZD1222) Recombinant replication competent vector that expresses S-protein

Collaboration between UQ, CSL & AU Government Abandoned due to false positive HIV tests

Manufacturing under contract to supply to AZ for AU

69

==> picture [84 x 95] intentionally omitted <==

What to Expect from Next-Generation Influenza Vaccines aQIVc Self-amplifying mRNA

70

Seqirus is Experienced in Protecting People from Seasonal Influenza Despite its Complicated Nature

==> picture [858 x 178] intentionally omitted <==

----- Start of picture text -----

4 Influenza Subtypes Frequent Antigenic Pre-existing Waning - Developing
co-circulate Drift Immunity Immune System
Protein + Adjuvant Self-amplifying mRNA
----- End of picture text -----

71

Improving Influenza Vaccines by Combining Two Advanced Technologies

==> picture [844 x 361] intentionally omitted <==

----- Start of picture text -----

aQIVc
MF59 [®] Adjuvant
Increases “breadth”
Cell-based Vaccine
Increases antibody response
MF59 [®] Adjuvanted Egg-
Dose-sparing potential (pandemic)
based Vaccine
Circulating
Strains
-
Egg based Vaccine
Cell Culture
Closer match to circulating strain
More efficient manufacture than egg
Greater flexibility – faster in pandemic
----- End of picture text -----

Antigenic Distance

72

Pulling Key Levers to Further Improve Protein-based Influenza Vaccines

==> picture [875 x 399] intentionally omitted <==

----- Start of picture text -----

Higher Antigen Dose MF59 [®] Adjuvant
Drives Higher Immunogenicity Drives Higher Immunogenicity
Hemagglutination Inhibition Titers GMT Ratio aTIV vs TIV
180 1.8
160
1.6 • ↑
125 Higher antigen dose drives
140
1.4 immune response
120 91
86
1.2
100 • MF59 [®] drives ↑ immune
80 61 1 response
50
60 0.8 • aQIVc combines benefits of
43
40 37 adjuvant, dose and cell-derived
23 0.6 antigen to increased influenza
20
0.4 protection
0
0.2
0
A/H1N1 A/H3N2
H1N1 H3N2 B/Vic
Source: Keitel, W. et al , (2006) Arch Intern Med 166: 1121-1127 Unpublished data, Seqirus
73 Abbreviations: GMT - Geometric Mean Titer; GMT - Geometric Mean Titer;
Favours aTIV
HAI GMTs
GMT Ratio aTIV vs TIV
Favours TIV
control 15 ug 30 ug 60 ug control 15 ug 30 ug 60 ug
----- End of picture text -----

Abbreviations: GMT - Geometric Mean Titer; GMT - Geometric Mean Titer; HAI - Hemagglutination Inhibition

RNA-based Vaccines Have Shown Value in SARS-CoV-2 Pandemic

==> picture [156 x 41] intentionally omitted <==

==> picture [537 x 60] intentionally omitted <==

==> picture [224 x 14] intentionally omitted <==

==> picture [599 x 97] intentionally omitted <==

==> picture [204 x 23] intentionally omitted <==

74

Seqirus Has a Long Research History in Self-amplifying mRNA

==> picture [71 x 60] intentionally omitted <==

==> picture [76 x 60] intentionally omitted <==

Research on viral targets (RSV, CMV, Flu, HIV) with multiple partners

==> picture [149 x 40] intentionally omitted <==

==> picture [147 x 83] intentionally omitted <==

H7N9 sa-mRNA vaccine made in 8 days from on-line sequence

==> picture [72 x 25] intentionally omitted <==

==> picture [126 x 84] intentionally omitted <==

H5N1 vaccine candidate generated

==> picture [155 x 78] intentionally omitted <==

COVID vaccine candidate generated

2008 Initiation of sa-mRNA research

==> picture [119 x 46] intentionally omitted <==

2012 DARPA funds platform development

==> picture [89 x 49] intentionally omitted <==

2015 SEQ continues Flu vaccine development

==> picture [131 x 54] intentionally omitted <==

2019 seasonal Flu into 2021 Pre-pandemic Development (H2) collaboration for sa-mRNA and cell culture platforms

==> picture [79 x 79] intentionally omitted <==

75

Abbreviations: CMV – Cytomegalovirus; HIV - Human Immunodeficiency Virus; RSV - Respiratory Syncytial Virus

mRNA Technology – Two Main Approaches Have Important Differences

Source: Adapted from Dolgin E. (2021) Nature 589(7841):189-191

76

Seasonal Influenza Challenges Differ from SARS-CoV-2

1 Circulating Unknown No Pre-existing COVID Virus Antigenic Drift Immunity Waning - Developing Immune System 4 Influenza Subtypes Frequent Pre-existing Flu co-circulate Antigenic Drift Immunity

Flu is more complicated; may expect efficacy lower than for SARS-CoV-2

77

sa-mRNA – Two Key Elements Drive Immune Responses

Self-amplifying mRNA payload

Lipid Nanoparticle (LNP)

Monocistronic = 1 gene of interest encoded by mRNA

Replicon Genes Gene of Interest

Bicistronic = 2 genes of interest encoded by mRNA

Replicon Genes Gene of Interest 1 Gene of Interest 2

==> picture [241 x 106] intentionally omitted <==

----- Start of picture text -----

Key lipids
LNP
mRNA
100 nm
----- End of picture text -----

• Ability to include multiple antigens means vaccine can have greater control of gene expression with increased safety

• With lower dose it is easier to include additional antigens on the same sa-mRNA

• Cationic Lipid is main component of LNP that mediates entry

• Cationic Lipid drives some reactogenicity, different companies have different lipids

78

sa-mRNA Platform Expresses More Protein than First Generation mRNA

==> picture [423 x 306] intentionally omitted <==

----- Start of picture text -----

In vivo Protein Expression
10 8 sa-mRNA-luc/LNP, 1 mcg luc mRNA/LNP, 1 mcg
6 h pi
10 7
10 6
10 5
10 4
10 3
0 7 14 21
days post vaccination
/sr)
2
Geo mean, 95% CI
Whole body radiance (p/s/cm
----- End of picture text -----

• sa-mRNA expresses 100+ fold more protein than mRNA

• sa-mRNA expression prolonged compared to mRNA

• Lower potential dose is benefit for influenza vaccines that require multiple strains

Unpublished data, Seqirus

79

More Engaged Immune System = More Protective Response

B-cell (Antibody) Response

Serum antibodies Mucosal antibodies (IgG) (IgA) Protect lungs Prevent infection

T-cell Response

==> picture [413 x 234] intentionally omitted <==

----- Start of picture text -----

CD4+ T cells CD8+ T cells
(T helper) (CTLs)
Increase B-cell Lyse virus-infected
cells
response
Reduce severity of infection
Cross strain reactivity
----- End of picture text -----

==> picture [194 x 35] intentionally omitted <==

----- Start of picture text -----

Protect against infection
Wane with age
----- End of picture text -----

CD8+ T-Cell responses to conserved epitopes add a new protective layer

80

sa-mRNA Platform Raises More Robust T-cell Responses (CD8+/CD4+) than mRNA

COVID sa-mRNA Vaccination Cellular Responses

==> picture [208 x 231] intentionally omitted <==

----- Start of picture text -----

CoV-2-S-specific CD8+ T cells
14 14
12 12
10 10
8 8
6 6
4 4
2 2
0 0
+ +
γ γ
CD8 T cells: % Ag-specific, IFN- CD8 T cells: % Ag-specific, IFN-
----- End of picture text -----

==> picture [31 x 12] intentionally omitted <==

==> picture [158 x 198] intentionally omitted <==

CoV-2-S-specific CD4+ T cells

==> picture [367 x 205] intentionally omitted <==

----- Start of picture text -----

1.2 1.2
1 1
0.8 0.8
0.6 0.6
0.4 0.4
0.2 0.2
0 0
CD4 T cells: % Ag-specific, TNF- CD4 T cells: % Ag-specific, TNF-
----- End of picture text -----

• sa-mRNA > Moderna mRNA (~5x-8x) published cellular responses

• S1 peptide mix used in similar experiments published by Moderna

CoV-2-S sa-mRNA (Seqirus) CoV-2-S mRNA (Moderna*)

*Moderna data; Corbett, K.S. et al., (2020) BioRxiv. Unpublished data, Seqirus

81

sa-mRNA Influenza Vaccine Induces Antibody Response Equal to MF59[®] Vaccine AND Superior CD8+ T-Cell Responses

Influenza Hemagglutination Inhibition

==> picture [302 x 214] intentionally omitted <==

----- Start of picture text -----

H1 H3 Bv By(c)
8192
2048
512
128
32
8
GMT
HAI titer
----- End of picture text -----

• sa-mRNA quadrivalent vaccines raise robust Hemagglutination Inhibition (HAI) titers

• Hemagglutinin, Neuraminidase (NA), Matrix, and Nucleoprotein all raise strong CD8+ and CD4+ responses

• Neuraminidase raises strong neutralization and NA-blocking antibody responses

==> picture [258 x 55] intentionally omitted <==

sa-mRNA Monovalent vaccine at 1 ug dose per target strain; sa-mRNA Quadrivalent vaccine at 1 ug dose per strain

Unpublished data, Seqirus

82

sa-mRNA SARS-CoV-2 Vaccines Protect Hamsters Against Viral Challenge

Lung virus titers (Day 4)

==> picture [253 x 325] intentionally omitted <==

Nasal turbinate titers (Day 4)

==> picture [278 x 325] intentionally omitted <==

Unpublished data, Seqirus

83

==> picture [84 x 95] intentionally omitted <==

Seqirus and Future Influenza Vaccine Portfolio

84

FY22 Seqirus Milestones

FLUCELVAX[®] QUAD

• Australia 2yr+ age extension approval

• Argentina 6mo+ age extension approval

FLUAD[®] QUAD

• Adult 50-64yr immunogenicity study start

aQIVc

• Phase II Older Adult study results

Self-amplifying mRNA

• Completion of GLP Tox study

Abbreviations: GLP – Good Laboratory Practice

85

The Promise and Challenges of New Influenza Vaccines

aQIVc has the potential to be the most effective differentiated influenza vaccine with currently approved technology

sa-mRNA provides great promise for influenza and is a high priority project for CSL/Seqirus

• Potential efficacy benefit, enhanced readiness (speed), simplification of manufacturing, antigen-agnostic technology readiness

• Challenges in influenza include efficacy ( influenza is not SARS-CoV-2 ), side-effects, stability, presentation

86

==> picture [55 x 99] intentionally omitted <==

Summary William Mezzanotte MD Executive Vice President, Head of R&D and Chief Medical Officer CSL Behring

==> picture [109 x 9] intentionally omitted <==

==> picture [35 x 19] intentionally omitted <==

87

R&D Portfolio – FY22

PhaseI PhaseII

Phase III

Registration/ Post-Registration

CSL324 HIZENTRA[®] Garadacimab HAEGARDA[®] AUDENZ™ Anti-G-CSFR mAb(HS) (SSc) Anti-FXIIa mAb(HAE) (HAE) Adjuvanted Monovalent Influenza A (H5N1) Vaccine CSL730 Garadacimab HIZENTRA[®] HIZENTRA[®] rFcMultimer Anti-FXIIa mAb(ILD/IPF) (DM) (SCIg) 20% Liquid AFLURIA[®] QUAD Egg-based Influenza CSL889 CSL346 EtranaDez PRIVIGEN[®] Vaccine Hemopexin(SCD) Anti-VEGF-B mAb Etranacogene (IVIg) 10% Liquid (DKD) dezaparvovec (Haem B) FLUAD[®] Trivalent CSL787 Adjuvanted Influenza AFSTYLA[®] NebulisedIg Adjuvanted Cell Culture KCENTRA[®] rFVIII (HaemA) Vaccine Influenza Vaccine 4F-PCC (Trauma) CSL311 FLUAD[®] Quadrivalent (aQIVc) IDELVION[®] Anti-Beta Common mAb Adjuvanted Influenza CSL1 1 2 rFIX-FP (HaemB) Vaccine Mavrilimumab apoA-I(AMI) ASLAN004 Anti-IL-13R mAb(AD) Anti-GM-CSFR mAb(GCA, COVID) Clazakizumab ZEMAIRA Alpha-1 Antitrypsin[®] /RESPREEZA[®] QuadrivalentFLUCELVAX[®] Anti-IL-6 mAb(AMR) Cell-based Influenza Vaccine CSL964 FOCLIVIA[®] /FOCETRIA PANVAX[®] Alpha-1Antitrypsin Adjuvanted Egg-based Egg-based Influenza Vaccine (Treatment of GvHD) Influenza A (H5N1) Vaccine CSL964 Alpha 1Antitrypsin (Prevention of GvHD)

Immunology Haematology Respiratory Cardiovascular & Metabolic Transplant Influenza Vaccines Outlicensed Programs Partnered Projects

88

Significant Target Launch Dates

==> picture [725 x 288] intentionally omitted <==

----- Start of picture text -----

FY23-
FY22
FY26
HAEGARDA [®] Garadacimab CSL112 Adjuvanted Cell Culture
Japan (HAE) Anti-FXIIa (HAE) ApoA-1 (AMI) Influenza Vaccine
(aQIVc)
HIZENTRA [®] Clazakizumab sa-mRNA Influenza
(DM) Anti-IL-6 (AMR) Vaccine (sa-mRNA)
IDELVION [®] CSL964 AAT
China (Haem B) (GvHD Treatment)
EtranaDez
Etranacogene
dezaparvovec (Haem B)
----- End of picture text -----

Immunology Haematology Cardiovascular & Metabolic Transplant Influenza Vaccines Partnered Projects

89

R&D Portfolio Highlights – FY22

==> picture [43 x 43] intentionally omitted <==

Immunology

• Garadacimab (Anti ~~-~~ FXIIa) complete Phase III HAE study enrolment

• CSL324 (Anti ~~-~~ G ~~-~~ CSFR) complete PK/Ethnicity study for SC formulation and inclusion of Japan

• HAEGARDA[®] submission to PMDA for treatment of HAE

• HIZENTRA[®] SID CLL initiate Phase III study

==> picture [43 x 43] intentionally omitted <==

Respiratory

• CSL311 (Anti ~~-~~ Beta Common) initiate POM study in mild asthmatic patients

• Garadacimab (Anti ~~-~~ FXIIa) initiate Phase II IPF study

==> picture [43 x 43] intentionally omitted <==

Haematology

• KCENTRA[®] initiate Phase III study for treatment of massive haemorrhage associated with severe traumatic injury

• EtranaDez (Haem B gene therapy) BLA/MAA submission (US/EU)

• IDELVION[®] rFIX ~~-~~ FP (Haem B) China CTA filing

• AFSTYLA[®] rFVIII (Haem A) China IND submission

==> picture [43 x 42] intentionally omitted <==

Cardiovascular and Metabolic

• CSL112 (apo A ~~-~~ I) complete 3[rd] interim analysis

• CSL346 (Anti ~~-~~ VEGF ~~-~~ B) complete enrolment Phase II POC study for DKD

==> picture [44 x 43] intentionally omitted <==

Transplant

• CSL964 (AAT) for prevention of GvHD initiate Phase III study

==> picture [44 x 43] intentionally omitted <==

Influenza Vaccines

• aQIVc (cell antigen + MF59[®] ) complete Phase II safety & immunogenicity study

• FLUCELVAX[®] Quadrivalent US approval 6mo+ indication

• FLUCELVAX[®] QUAD Australia 2yr+ extension approval

• FLUAD[®] Quadrivalent Adults 50 ~~-~~ 64yr initiate Phase III study

• CSL787 (NebIg) complete Phase I study

90

==> picture [101 x 89] intentionally omitted <==

Panel Q&A Session

==> picture [960 x 90] intentionally omitted <==